MDS Podcast
Avsnitt

Setting the TEMPO: What have we learned about D1/D5 dopamine stimulation in Parkinson’s disease?

MDS Podcast
Dela

Dr. Divyani Garg speaks with Dr. Hubert H. Fernandez about tavapadon, a once-daily selective dopamine D1/D5 receptor agonist, and what the TEMPO clinical development program tells us about its potential role in Parkinson’s disease (PD). They discuss the rationale for D1/D5 stimulation, findings from other TEMPO programs, the magnitude and clinical meaning of the motor benefit, flexible dosing, and the important tolerability and discontinuation findings from TEMPO-2. The conversation also explores where tavapadon might fit relative to levodopa and conventional D2/D3 dopamine agonists, and its potential role across different stages of PD.

Read the article.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör International Parkinson and Movement Disorder Society. Innehållet i podden är skapat av International Parkinson and Movement Disorder Society och inte av, eller tillsammans med, Poddtoppen.